Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have earned an average recommendation of "Buy" from the eight ratings firms that are currently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $11.60.

A number of equities research analysts recently issued reports on the company. Wall Street Zen downgraded Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Immunic in a report on Thursday, May 1st. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 target price on shares of Immunic in a report on Wednesday, June 25th. B. Riley reaffirmed a "buy" rating and issued a $5.00 target price (down previously from $6.00) on shares of Immunic in a report on Friday, May 23rd. Finally, William Blair reaffirmed an "outperform" rating on shares of Immunic in a report on Friday, May 16th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Invesco Ltd. bought a new position in shares of Immunic in the 4th quarter valued at $37,000. Barclays PLC bought a new position in shares of Immunic in the 4th quarter valued at $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Immunic by 90.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock valued at $205,000 after acquiring an additional 96,894 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Immunic by 279.3% in the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock valued at $226,000 after acquiring an additional 152,726 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its stake in shares of Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after acquiring an additional 22,200 shares during the last quarter. 51.82% of the stock is currently owned by institutional investors.

Immunic Price Performance

Shares of NASDAQ:IMUX opened at $0.73 on Friday. The company has a market capitalization of $69.85 million, a P/E ratio of -0.59 and a beta of 1.49. Immunic has a 1 year low of $0.56 and a 1 year high of $2.11. The business's 50 day simple moving average is $0.87 and its 200 day simple moving average is $0.99.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.25). On average, sell-side analysts anticipate that Immunic will post -0.94 EPS for the current fiscal year.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.